<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <script src="https://cdnjs.cloudflare.com/ajax/libs/Chart.js/3.7.0/chart.min.js"></script>
    <title>MS Clinical Intelligence Dashboard</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
            font-family: system-ui, -apple-system, sans-serif;
        }

        body {
            background-color: #f5f7fa;
            min-height: 100vh;
            padding: 2rem;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            background-color: white;
            border-radius: 1rem;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            padding: 2rem;
        }

        .header {
            text-align: center;
            margin-bottom: 3rem;
            padding: 2rem;
            background: linear-gradient(135deg, #2c3e50, #3498db);
            border-radius: 0.5rem;
            color: white;
        }

        .header h1 {
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: 0.5rem;
        }

        .section-title {
            font-size: 1.5rem;
            color: #2c3e50;
            margin-bottom: 2rem;
            padding-bottom: 0.5rem;
            border-bottom: 2px solid #3498db;
        }

        .timeline {
            position: relative;
            padding: 2rem 0;
            border-bottom: 2px solid #3498db;
        }

        .timeline-line {
            position: absolute;
            top: 50%;
            left: 0;
            right: 0;
            height: 4px;
            background: #070707;
            transform: translateY(-50%);
        }

        .timeline-points {
            position: relative;
            display: flex;
            justify-content: space-between;
            margin: 0 2rem;
        }

        .timeline-point {
            position: relative;
            display: flex;
            flex-direction: column;
            align-items: center;
            width: 200px;
        }

        .point {
            width: 20px;
            height: 20px;
            border-radius: 50%;
            margin: 1rem 0;
            z-index: 1;
        }

        .year {
            font-weight: 600;
            margin-bottom: 1rem;
            color: #2c3e50;
        }

        .description {
            text-align: center;
            font-size: 0.7rem;
            font-weight: bold ;
            color: #555;
            margin-top: 1rem;
            padding: 0.5rem;
            border-radius: 0.5rem;
            min-height: 80px;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .timeline-point:nth-child(1) .point { background-color: #3498db; }
        .timeline-point:nth-child(2) .point { background-color: #2ecc71; }
        .timeline-point:nth-child(3) .point { background-color: #e74c3c; }
        .timeline-point:nth-child(4) .point { background-color: #f1c40f; }
        .timeline-point:nth-child(5) .point { background-color: #9b59b6; }
        .timeline-point:nth-child(6) .point { background-color: #1abc9c; }

        .timeline-point:nth-child(odd) .description {
            background-color: #f8f9fa;
        }

        .timeline-point:nth-child(even) .description {
            background-color: #e9ecef;
        }
        .timeline-point {
            position: relative;
            display: flex;
            flex-direction: column;
            align-items: center;
            width: 200px;
        }

        .timeline-point::before {
            content: '';
            position: absolute;
            top: 40%;
            width: 3px;
            height: 30px;
            background-color: #3498db;
            z-index: 0;
        }

        .container_grid {
            max-width: 1200px;
            margin: 20px auto; /* Added 20px margin on top */
            padding: 20px;
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
        }


        .moa-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 30px;
        }

        .moa-button {
            background: white;
            border: 1px solid #e1e4e8;
            border-radius: 8px;
            padding: 15px;
            display: flex;
            align-items: center;
            cursor: pointer;
            transition: all 0.3s ease;
            position: relative;
            overflow: hidden;
        }

        .moa-button::after {
            content: '';
            position: absolute;
            width: 100%;
            height: 100%;
            top: 0;
            left: 0;
            background: rgba(255,255,255,0.1);
            transform: translateX(-100%);
            transition: transform 0.3s ease;
        }

        .moa-button:hover {
            transform: translateY(-2px);
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }

        .moa-button:hover::after {
            transform: translateX(0);
        }

        .moa-icon {
            width: 40px;
            height: 40px;
            border-radius: 8px;
            margin-right: 15px;
            flex-shrink: 0;
        }

        .immunomodulators { background-color: #4299e1; }
        .btk-inhibitors { background-color: #48bb78; }
        .s1p-modulators { background-color: #ed8936; }

        .moa-name {
            flex-grow: 1;
            font-weight: 600;
            color: #2d3748;
        }

        .dropdown-arrow {
            color: #718096;
            transition: transform 0.3s ease;
        }

        .active .dropdown-arrow {
            transform: rotate(180deg);
        }

        .moa-details {
            background: white;
            border-radius: 8px;
            padding: 20px;
            margin-top: 20px;
            display: none;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
        }

        .metrics-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 20px;
            margin-bottom: 30px;
        }

        .metric-card {
            background: #f8fafc;
            border-radius: 8px;
            padding: 20px;
            text-align: center;
        }

        .metric-value {
            font-size: 24px;
            font-weight: 700;
            color: #2d3748;
            margin: 10px 0;
        }

        .charts-section {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 20px;
            margin-bottom: 30px;
        }

        .chart-container {
            background: white;
            border-radius: 8px;
            padding: 20px;
        }

        @media (max-width: 768px) {
            .charts-section {
                grid-template-columns: 1fr;
            }
            
            .metrics-grid {
                grid-template-columns: 1fr;
            }
        }
        .container-tb {
        max-width: 1200px;
        margin: 0 auto;
        background: white;
        border-radius: 12px;
        box-shadow: 0 1px 3px rgba(0,0,0,0.1);
        padding: 20px;
    }

        table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
        }

        th {
            background: #f1f5f9;
            padding: 16px;
            text-align: left;
            font-weight: 600;
            color: #334155;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 16px;
            border-bottom: 1px solid #e2e8f0;
            vertical-align: top;
        }

        .drug-row {
            cursor: pointer;
            transition: all 0.2s ease;
        }

        .drug-row:hover {
            background-color: #f8fafc;
        }

        .drug-row.active {
            background-color: #f1f5f9;
            border-bottom: none;
        }

        .drug-name {
            display: flex;
            align-items: center;
            gap: 12px;
            font-weight: 500;
            color: #1e40af;
        }

        .drug-icon {
            width: 24px;
            height: 24px;
            display: flex;
            align-items: center;
            justify-content: center;
            transition: transform 0.3s ease;
            color: #64748b;
        }

        .drug-row.active .drug-icon {
            transform: rotate(180deg);
        }

        .drug-insights {
            display: none;
            background: #f8fafc;
        }

        .drug-insights td {
            padding: 0;
        }

        .drug-insights.show {
            display: table-row;
        }

        .insights-container {
            padding: 20px;
            border-top: 2px solid #e2e8f0;
        }

        .insights-section {
            background: white;
            border-radius: 8px;
            padding: 20px;
            margin-bottom: 16px;
            box-shadow: 0 1px 2px rgba(0,0,0,0.05);
        }

        .insights-section:last-child {
            margin-bottom: 0;
        }

        .insights-section h4 {
            color: #334155;
            margin: 0 0 12px 0;
            font-size: 1rem;
            display: flex;
            align-items: center;
            gap: 8px;
        }

        .insights-section h4::before {
            content: "•";
            color: #3b82f6;
        }

        .insights-section p {
            margin: 0;
            color: #475569;
        }

        .trial-button {
            background: #e2e8f0;
            border: 1px solid #cbd5e1;
            padding: 8px 16px;
            border-radius: 6px;
            margin-right: 8px;
            margin-top: -2px;
            margin-bottom: 6px;
            cursor: pointer;
            font-size: 0.875rem;
            color: #334155;
            transition: all 0.2s ease;
            font-weight: 500;
        }

        .trial-button:hover {
            background: #cbd5e1;
            border-color: #94a3b8;
        }

        .trial-button.active {
            background: #bfdbfe;
            border-color: #60a5fa;
            color: #1e40af;
        }

        .trial-insights {
            display: none;
            background: white;
        }

        .trial-insights.show {
            display: table-row;
        }

        .trial-insights .insights-section {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
        }

        .phase-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 5px;
            padding: 6px 12px;
            border-radius: 6px;
            background: #f9f9f9;
            color: #1e40af;
            font-size: 0.875rem;
            font-weight: 500;
        }

        .company-cell {
            color: #64748b;
            text-shadow: #2d3748;
        }

        /* Additional styles for better visibility of active states */
        .drug-row td {
            border-bottom: 1px solid #e2e8f0;
            transition: border-color 0.2s ease;
        }

        .drug-row.active td {
            border-bottom-color: transparent;
        }

        .trial-insights td {
            padding: 0 16px 16px 16px;
        }
        .timeline-container-inner {
            max-width: 1200px;
            margin: 200px auto 20px auto;
        }

        .timeline-inner {
            position: relative;
            padding: 60px 0;
        }

        /* Main horizontal line */
        .timeline-inner::before {
            content: '';
            position: absolute;
            margin-top: -115px;
            left: 0;
            right: 0;
            top: 50%;
            height: 4px;
            background: #3498db;
            transform: translateY(-50%);
        }

        .timeline-items-inner {
            display: flex;
            justify-content: space-between;
            position: relative;
        }

        .timeline-item-inner {
            flex: 1;
            position: relative;
            padding: 0 20px;
            text-align: center;
        }

        /* Dots on the line */
        .timeline-dot-inner {
            width: 20px;
            height: 20px;
            background: #fff;
            border: 4px solid #3498db;
            border-radius: 50%;
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            z-index: 1;
        }

        /* Content boxes */
        .timeline-content-inner {
            background: white;
            padding: 20px;
            border-radius: 8px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            margin: 50px 0;
            position: relative;
        }

        /* Alternating content boxes */
        .timeline-item-inner:nth-child(odd) .timeline-content-inner {
            margin-top: 50px;
        }

        .timeline-item-inner:nth-child(even) .timeline-content-inner {
            margin-top:-180px;
        }

        /* Vertical connector lines */
        .timeline-item-inner:nth-child(odd) .timeline-content-inner::before {
            content: '';
            position: absolute;
            top: -30px;
            left: 50%;
            width: 1px;
            height: 30px;
            background: #3498db;
            transform: translateX(-50%);
        }

        .timeline-item-inner:nth-child(even) .timeline-content-inner::before {
            content: '';
            position: absolute;
            bottom: -30px;
            left: 50%;
            width: 1px;
            height: 30px;
            background: #3498db;
            transform: translateX(-50%);
        }

        .timeline-year-inner {
            font-size: 1rem;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 10px;
        }

        .timeline-description-inner {
            color: #666;
            line-height: 1.5;
            font-size: 0.8rem;
            font-weight: bold;
        }

        @media (max-width: 768px) {
            .timeline-items-inner {
                flex-direction: column;
            }

            .timeline-item-inner {
                margin-bottom: 40px;
            }

            .timeline-item-inner:nth-child(even) .timeline-content-inner,
            .timeline-item-inner:nth-child(odd) .timeline-content-inner {
                margin-top: 20px;
            }
        }
        .latest-insights {
            max-width: 1200px;
            margin: 30px auto;
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
            padding: 25px;
        }

        .latest-insights h2 {
            color: #2d3748;
            margin-bottom: 20px;
            font-size: 1.5rem;
            font-weight: 600;
        }

        .insight-category {
            margin-bottom: 15px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            overflow: hidden;
        }

        .insight-header {
            display: flex;
            align-items: center;
            justify-content: space-between;
            padding: 15px 20px;
            background-color: #f8fafc;
            cursor: pointer;
            transition: background-color 0.3s ease;
        }

        .insight-header:hover {
            background-color: #f1f5f9;
        }

        .header-title {
            font-weight: 600;
            color: #2d3748;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .header-title .category-icon {
            width: 24px;
            height: 24px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 6px;
        }

        .clinical .category-icon {
            background-color: #ebf5ff;
            color: #3182ce;
        }

        .regulatory .category-icon {
            background-color: #f0fff4;
            color: #38a169;
        }

        .safety .category-icon {
            background-color: #fff5f5;
            color: #e53e3e;
        }

        .market .category-icon {
            background-color: #faf5ff;
            color: #805ad5;
        }

        .toggle-btn {
            width: 24px;
            height: 24px;
            border-radius: 50%;
            background-color: #ffffff;
            border: 1px solid #e2e8f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            transition: all 0.3s ease;
            font-size: 18px;
            color: #64748b;
        }

        .toggle-btn:hover {
            background-color: #f8fafc;
            transform: scale(1.1);
        }

        .insight-content {
            max-height: 0;
            overflow: auto;
            transition: max-height 0.3s ease-out;
            background-color: white;
        }

        .insight-content.active {
            max-height: 500px;
            transition: max-height 0.5s ease-in;
        }

        .insight-list {
            padding: 20px;
        }

        .insight-item {
            display: flex;
            gap: 15px;
            padding: 12px;
            border-bottom: 1px solid #f1f5f9;
        }

        .insight-item:last-child {
            border-bottom: none;
        }

        .insight-date {
            min-width: 100px;
            color: #64748b;
            font-size: 0.9rem;
        }

        .insight-description {
            color: #4a5568;
            line-height: 1.5;
            flex-grow: 1;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 0.75rem;
            font-weight: 500;
            margin-left: 8px;
        }

        .badge.new {
            background-color: #ebf5ff;
            color: #3182ce;
        }

        .badge.update {
            background-color: #f0fff4;
            color: #38a169;
        }

    </style>
</head>
<body>
    <div class="container">
        <header class="header">
            <h1>Clinical Intelligence - Multiple Sclerosis</h1>
        </header>

        <section>
            <h2 class="section-title">MS Treatment Development Timeline</h2>
            <div class="timeline">
                <div class="timeline-line"></div>
                <div class="timeline-points">
                    <div class="timeline-point">
                        <div class="year">2019</div>
                        <div class="point"></div>
                        <div class="description">BTK inhibitors transform treatment.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2020</div>
                        <div class="point"></div>
                        <div class="description">Improved anti-CD20 targeting.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2021</div>
                        <div class="point"></div>
                        <div class="description">New Safer S1P modulators.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2022</div>
                        <div class="point"></div>
                        <div class="description">Remyelination breakthrough.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2023</div>
                        <div class="point"></div>
                        <div class="description">Microglial modulation advances.</div>
                    </div>
                    <div class="timeline-point">
                        <div class="year">2024</div>
                        <div class="point"></div>
                        <div class="description">Combined immune-regeneration therapy.</div>
                    </div>
                </div>
            </div>
        </section>
    </div>

    <div class="container_grid">
        <h2 class="section-title">Mechanism Of Actions</h2>
        <div class="moa-grid">
            <div class="moa-button" onclick="toggleMOA('anticd20', this)">
                <div class="moa-icon immunomodulators"></div>
                <span class="moa-name">Anti CD20 monoclonal antibody</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('btk', this)">
                <div class="moa-icon btk-inhibitors"></div>
                <span class="moa-name">BTK Inhibitors</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon s1p-modulators"></div>
                <span class="moa-name">S1P Modulators</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon immunomodulators"></div>
                <span class="moa-name">DHODH Inhibitors</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon btk-inhibitors"></div>
                <span class="moa-name">Immunomodulators</span>
                <span class="dropdown-arrow">▼</span>
            </div>
            <div class="moa-button" onclick="toggleMOA('s1p', this)">
                <div class="moa-icon s1p-modulators"></div>
                <span class="moa-name">Anti CD40L monoclonal antibody </span>
                <span class="dropdown-arrow">▼</span>
            </div>
        </div>

        <!-- BTK Inhibitors -->
        <div id="btk-details" class="moa-details">
            <h3 class="section-title">BTK Inhibitors</h3>
            <div class="metrics-grid">
                <div class="metric-card">
                    <h3>Total Trials</h3>
                    <div class="metric-value">10</div>
                </div>
                <div class="metric-card">
                    <h3>Total Competitors</h3>
                    <div class="metric-value">5</div>
                </div>
                <div class="metric-card">
                    <h3>Drug Count</h3>
                    <div class="metric-value">5</div>
                </div>
            </div>

            <div class="charts-section">
                <div class="chart-container">
                    <canvas id="btk-phase-chart"></canvas>
                </div>
                <div class="chart-container">
                    <canvas id="btk-market-chart"></canvas>
                </div>
            </div>
            <h2 class="section-title">BTK Inhibitors Time Line</h2>
            <div class="timeline-container-inner">
                <div class="timeline-inner">
                    <div class="timeline-items-inner">
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2019</div>
                                <div class="timeline-description-inner">
                                    Evobrutinib's efficacy in reducing MS lesions.
                                </div>
                            </div>
                        </div>
            
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2020</div>
                                <div class="timeline-description-inner">
                                    Olebrutinib shows CNS penetration, lesion reduction.
                                </div>
                            </div>
                        </div>
            
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2021</div>
                                <div class="timeline-description-inner">
                                    Fenebrutinib begins pivotal Phase III trials.
                                </div>
                            </div>
                        </div>
            
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2022</div>
                                <div class="timeline-description-inner">
                                    Evobrutinib outperforms teriflunomide in Phase III.
                                </div>
                            </div>
                        </div>
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2023</div>
                                <div class="timeline-description-inner">
                                    Tolebrutinib effective in progressive MS.
                                </div>
                            </div>
                        </div>
                        <div class="timeline-item-inner">
                            <div class="timeline-dot-inner"></div>
                            <div class="timeline-content-inner">
                                <div class="timeline-year-inner">2024</div>
                                <div class="timeline-description-inner">
                                    Advanced selective BTK inhibitors emerge.
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>        

            <h2 class="section-title">Drug / Molecule Details</h2>
            <div class="container">
                <table>
                    <thead>
                        <tr>
                            <th>Drug Name</th>
                            <th>Company</th>
                            <th>Trial Count</th>
                            <th>Trial IDs and Phase</th>
                        </tr>
                    </thead>
                    <tbody>
                        <!-- Drug 1 -->
                        <tr class="drug-row" data-drug="remibrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Remibrutinib
                                </div>
                            </td>
                            <td class="company-cell">Novartis</td>
                            <td><span class="phase-badge">2</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05156281">NCT05156281<span class="phase-badge">Phase - III</span></button>
                                <button class="trial-button" data-trial="NCT05147220">NCT05147220<span class="phase-badge">Phase - III</span></button>
                            </td>
                        </tr>
                        
                        <tr id="remibrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p><li>Recent advancements in multiple sclerosis (MS) research have garnered attention from key opinion leaders, with an emphasis on the need for diverse treatment approaches beyond conventional Disease-Modifying Therapies (DMTs). </li>
                                        <li>Experts highlight the importance of early intervention, noting that combining different therapies—such as aryl hydrocarbon receptor modulators—could enhance immune tolerance and potentially improve outcomes for MS patients. These insights align with an increasing demand for personalized MS treatments that address varied patient needs and conditions, offering a potential leap in long-term symptom management</li></p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p><li>Novartis is preparing to submit regulatory filings for remibrutinib as a treatment for Multiple Sclerosis in the second half of 2024. This comes on the heels of encouraging results from recent clinical trials that demonstrated remibrutinib's effectiveness in managing MS symptoms. </li>
                                        <li>The company aims to position remibrutinib as a key player in the evolving landscape of MS therapies, especially as it looks to replace older treatments nearing patent expiration.</li></p>
                                    </div>
                                </div>
                            </td>
                        </tr>
        
                        <!-- Trial Insights -->
                        <tr id="NCT05156281-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05156281</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The Phase 3 trial NCT05156281, led by Novartis, is evaluating remibrutinib's efficacy in reducing relapse rates and disability progression in relapsing multiple sclerosis (MS), comparing it to teriflunomide over two years. Interim findings show remibrutinib has a favorable safety profile across autoimmune conditions, reinforcing its promise for MS. The trial is currently recruiting participants and will track MRI changes, neurofilament levels, and physical function as secondary outcomes​
                                    </p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT05147220-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05147220</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The Phase III trials REMODEL I and II (NCT05147220) are evaluating the efficacy and safety of remibrutinib, a BTK inhibitor, in patients with relapsing multiple sclerosis (MS). These studies aim to compare remibrutinib with teriflunomide, a standard MS treatment, focusing on safety, tolerability, and efficacy across a large patient population. Both trials are being conducted globally with active recruitment in multiple countries, and preliminary discussions highlight remibrutinib’s potential in modulating B-cell-driven inflammation, a critical factor in MS progression​</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT72382624-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05147220</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>Latest results Will be Updated</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug -2 -->
                        <tr class="drug-row" data-drug="fenebrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Fenebrutinib
                                </div>
                            </td>
                            <td class="company-cell">Roche</td>
                            <td><span class="phase-badge">3</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05119569">NCT05119569<span class="phase-badge">Phase - II</span></button>
                                <button class="trial-button" data-trial="NCT04586023">NCT04586023<span class="phase-badge">Phase - II</span></button>
                                <button class="trial-button" data-trial="NCT04586010">NCT04586010<span class="phase-badge">Phase - III</span></button>
                            </td>
                        </tr>
                        <tr id="fenebrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>KOLs have noted fenebrutinib’s potential to reshape MS treatment due to its dual action on B-cells and microglia, which may address both MS disease activity and progression. Dr. Levi Garraway, Roche's Chief Medical Officer, emphasized that fenebrutinib has the potential to suppress nearly all disease activity in people with MS and could become a major player if Phase III results confirm these early findings</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Fenebrutinib is currently advancing through Phase III trials, with results expected by late 2025. These trials, known as FENhance 1 & 2, are evaluating fenebrutinib in relapsing multiple sclerosis (RMS), and FENtrepid is examining its efficacy in primary progressive MS (PPMS). If successful, fenebrutinib could follow Ocrevus as a significant treatment option, especially given its promising data on reducing both inflammation and disability progression.</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT05119569-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05119569</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>The Phase II FENopta study (NCT05119569) investigated Roche’s drug fenebrutinib in relapsing MS patients, showing a 69% reduction in new gadolinium-enhancing lesions and a 74% reduction in NET2 lesions compared to placebo over 12 weeks. By Week 12, reductions reached 90% for Gd+ lesions and 95% for NET2 lesions. Mean CSF concentration of fenebrutinib was 43.1 ng/mL, well above active ranges in blood assays, indicating effective central nervous system penetration. The drug demonstrated a favorable safety profile with no serious adverse events reported.</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04586023-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04586023</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>The trial for fenebrutinib (NCT04586023), a selective Bruton’s tyrosine kinase (BTK) inhibitor by Roche, targeted patients with progressive multiple sclerosis (MS). Results from the Phase II study showed positive outcomes, with fenebrutinib achieving the primary endpoint of reducing new gadolinium-enhancing T1 brain lesions, a marker of active inflammation, and the secondary endpoint of reducing T2 brain lesions, which indicate disease burden. No new safety concerns were identified, reinforcing fenebrutinib's established safety profile. These results underscore fenebrutinib's potential as a treatment to address inflammation and disability progression in MS</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04586010-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04586010</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The clinical trial NCT04586010, known as the FENtrepid study, investigates the efficacy of fenebrutinib in treating primary progressive multiple sclerosis (PPMS). This large, randomized, double-blind trial aims to enroll up to 946 patients, testing fenebrutinib against both placebo and ocrelizumab over 120 weeks. The primary goal is to assess disability progression over a 12-week period, with secondary measures including changes in brain volume and physical impacts reported by participants. Early data shows fenebrutinib’s ability to reduce new inflammatory lesions and suggests it penetrates the brain effectively, targeting key immune cells like B-cells and microglia, which drive inflammation in MS</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 3 -->
                        <tr class="drug-row" data-drug="tolebrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Tolebrutinib
                                </div>
                            </td>
                            <td class="company-cell">Sanofi</td>
                            <td><span class="phase-badge">3</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT03996291">NCT03996291<span class="phase-badge">Phase - III</span></button>
                                <button class="trial-button" data-trial="NCT04458051">NCT04458051<span class="phase-badge">Phase - III</span></button>
                                <button class="trial-button" data-trial="NCT04411641">NCT04411641<span class="phase-badge">Phase - III</span></button>
                            </td>
                        </tr>
                        <tr id="tolebrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Experts are optimistic about tolebrutinib’s potential. Dr. Jiwoh Oh from the University of Toronto emphasized the drug’s ability to stabilize relapse rates and limit new lesions. Sanofi's Dr. Erik Wallström highlighted its brain penetration and impact on MS disease progression, particularly in its ability to modulate inflammatory signaling in the brain</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Tolebrutinib is currently undergoing evaluation in several phase 3 trials, including the GEMINI studies for relapsing MS and the HERCULES trial for non-relapsing secondary progressive MS (nrSPMS). However, a partial FDA clinical hold was implemented in 2022 due to concerns about drug-induced liver injury, impacting the timeline for approval. Sanofi aims to file for regulatory approval by the end of 2024</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT03996291-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT03996291</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The open-label extension trial (NCT03996291) of tolebrutinib showed promising results for people with relapsing forms of multiple sclerosis (MS). In this study, tolebrutinib led to significant reductions in relapse rates, stabilized disability progression, and reduced brain lesion counts over time. The trial findings support tolebrutinib's potential as a beneficial oral BTK inhibitor for addressing smoldering neuroinflammation in relapsing MS. Sanofi aims to advance its regulatory plans based on this positive safety and efficacy profile.</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04458051-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04458051</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The PERSEUS trial is a Phase 3 study evaluating tolebrutinib, Sanofi's BTK inhibitor, in patients with primary progressive multiple sclerosis (PPMS). It aims to determine if tolebrutinib can delay confirmed disability progression compared to a placebo. The trial results, expected in late 2025, will provide additional insights into the drug’s effectiveness in slowing disability progression in PPMS, addressing an unmet need for treatments in progressive MS.</p>
                                </div>
                            </td>
                        </tr>
                        <tr id="NCT04411641-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04411641</h4>
                                    <p>Trial Phase: Phase III</p>
                                    <p>The HERCULES Phase 3 trial evaluated tolebrutinib's effects on disability progression in non-relapsing secondary progressive MS (SPMS). Results showed a 31% reduction in disability progression risk and an 88% improvement in six-month confirmed disability improvement rates for patients on tolebrutinib compared to placebo. Although it reduced brain lesions by 38%, tolebrutinib did not significantly slow brain tissue loss. Safety monitoring was increased due to liver enzyme concerns</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 4 -->
                        <tr class="drug-row" data-drug="orelabrutinib">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Orelabrutinib
                                </div>
                            </td>
                            <td class="company-cell">Beijing InnoCare Pharma</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT04711148">NCT04711148<span class="phase-badge">Phase - II</span></button>
                            </td>
                        </tr>
                        <tr id="orelabrutinib-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Key opinion leaders (KOLs) have expressed optimism regarding orelabrutinib's unique characteristics, such as its ability to penetrate the blood-brain barrier and its high selectivity for BTK. Dr. Alfred Sandrock, Head of Research and Development at Biogen, has highlighted the potential for orelabrutinib to offer clinically meaningful benefits by addressing the underlying biology of MS, thus improving treatment outcomes. KOLs suggest that these advantages may differentiate orelabrutinib from other BTK inhibitors currently in development</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>Orelabrutinib has been approved in China for relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is also advancing through global trials, with a Phase III trial initiated for primary progressive multiple sclerosis (PPMS) . In addition, InnoCare is expanding its trials to other autoimmune diseases, such as systemic lupus erythematosus (SLE) and immune thrombocytopenia purpura (ITP)</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT04711148-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT04711148</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>InnoCare Pharma's Phase 2 trial results show that orelabrutinib led to a significant, dose-dependent reduction in new active brain lesions in RRMS patients, with up to a 92.1% reduction in the highest dose group (80 mg daily). This 12-week interim analysis indicates that orelabrutinib met its primary objective, supporting further development. Compared to similar BTK inhibitors, it demonstrated competitive efficacy and a favorable safety profile.</p>
                                </div>
                            </td>
                        </tr>
                        <!-- Drug 5 -->
                        <tr class="drug-row" data-drug="biib091">
                            <td>
                                <div class="drug-name">
                                    <span class="drug-icon">▼</span>
                                    Biib091
                                </div>
                            </td>
                            <td class="company-cell">Biogen</td>
                            <td><span class="phase-badge">1</span></td>
                            <td>
                                <button class="trial-button" data-trial="NCT05798520">NCT05798520<span class="phase-badge">Phase - II</span></button>
                            </td>
                        </tr>
                        <tr id="biib091-insights" class="drug-insights">
                            <td colspan="4">
                                <div class="insights-container">
                                    <div class="insights-section">
                                        <h4>KOL Opinion</h4>
                                        <p>Key opinion leaders (KOLs), such as Dr. Diana Gallagher, head of Biogen's MS and Immunology Department, have highlighted BIIB091’s potential. It is a reversible, non-covalent BTK inhibitor, which is designed to target both B cells and myeloid cells. According to KOLs, this dual-targeting mechanism could offer advantages over traditional B-cell depleting agents by providing enhanced efficacy while avoiding long-term safety concerns</p>
                                    </div>
                                    <div class="insights-section">
                                        <h4>Regulatory Information</h4>
                                        <p>The trial is currently in Phase 2, and its estimated completion date is November 2026. No major regulatory submissions have been made as of now, as the focus remains on gathering safety and efficacy data. BIIB091's development is being closely monitored, and if the results are positive, regulatory milestones such as submission for FDA approval could follow after the Phase 2 and subsequent trials</p>
                                </div>
                            </td>
                        </tr>
        
                        <tr id="NCT05798520-insights" class="trial-insights">
                            <td colspan="4">
                                <div class="insights-section">
                                    <h4>Trial Information: NCT05798520</h4>
                                    <p>Trial Phase: Phase II</p>
                                    <p>The Phase 2 FUSION trial (NCT05798520) for Biogen's BIIB091 is currently in progress and focuses on relapsing forms of multiple sclerosis (MS). The study is assessing both BIIB091 as a monotherapy and in combination with Diroximel Fumarate (DRF), an approved MS therapy. Early-stage studies (SAD and MAD) have shown promising results in terms of B-cell suppression, which is critical in MS treatment. The primary endpoint in the first part of the trial is safety, while the second part focuses on MRI-based reductions in brain inflammation. The trial is expected to enroll 275 patients, with results expected by 2026</p>
                                </div>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="latest-insights">
                <h2>Latest Insights</h2>
                
                <!-- Clinical Breakthroughs -->
                <div class="insight-category">
                    <div class="insight-header clinical" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">🔬</span>
                            Clinical Breakthroughs
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <!-- <div class="insight-item">
                                <span class="insight-date">Oct 20, 2024</span> -->
                                <!-- <div class="insight-description">
                                   <strong>BTK inhibitors are gaining attention as a novel therapeutic approach for MS</strong> 
                                    <br>
                                    <li>BTK inhibitors like evobrutinib, tolebrutinib, and orelabrutinib are emerging as promising therapies for multiple sclerosis. These agents modulate B-cell activity and immune responses across the blood-brain barrier, aiming to address the autoimmune processes underlying MS. Early trials suggest potential in reducing MS-related inflammation and lesion formation.
                                    </li>
                                    
                                </div>
                            </div> -->
                            <div class="insight-item">
                                <!-- <span class="insight-date">Oct 15, 2024</span> -->
                                <div class="insight-description">
                                <strong> Clinical Efficacy: Several BTK inhibitors are undergoing investigation</strong> 
                                    <br>
                                    <li><span class="insight-date">Evobrutinib (Merck KGaA/EMD Serono): Showed acceptable tolerability and maintained efficacy in a phase 2 study over 2.5 years, although it failed to meet primary endpoints in subsequent phase 3 trials.</span>
                                    <li><span class="insight-date">Fenebrutinib (Roche): Demonstrated significant reductions in MRI markers of MS activity and a favorable safety profile, although it faced safety concerns related to liver function.</span></li>
                                    <li><span class="insight-date">Tolebrutinib (Sanofi): Reported a 60 mg/d dosage reduced T1 gadolinium-enhancing lesions by approximately 85%, with stable Expanded Disability Status Scale (EDSS) scores over time.</span></li>
                                    <li><span class="insight-date">Orelabrutinib (Beijing InnoCare Pharma): In a Phase 2 trial, Orelabrutinib demonstrated a significant reduction in new active brain lesions by 90% over a 12-week period. This promising result supports further development of Orelabrutinib for MS.</span></li>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            
                <!-- Safety and Tolerability -->
                <div class="insight-category">
                    <div class="insight-header regulatory" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">🛡️</span>
                            Safety and Tolerability
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <div class="insight-description">
                                    <li><strong>Novaritis: </strong>The Novartis-sponsored trials NCT05156281 and NCT05147220 are evaluating the safety, tolerability, and efficacy of remibrutinib versus teriflunomide in relapsing multiple sclerosis (RMS). Initial data indicate that remibrutinib may offer a manageable safety profile with fewer gastrointestinal and hematologic side effects than some other treatments. Both studies are tracking immune-related adverse events, liver enzyme levels, and infection rates. Final conclusions on safety and tolerability are expected upon study completion.</li>
                                    <br>
                                    <li><strong>Roche: </strong>Roche's fenebrutinib trials in relapsing multiple sclerosis (NCT05119569, NCT04586023, NCT04586010) have shown a favorable safety profile with minimal adverse effects. The Phase 2 FENopta study reported nearly complete suppression of active brain lesions in 99% of patients and a low annual relapse rate of 0.04, highlighting fenebrutinib's efficacy. There were no new safety concerns, reinforcing its potential as a BTK inhibitor for MS treatment.</li>
                                    <br>
                                    <li><strong>Sanofi: </strong>Sanofi's trials (NCT03996291, NCT04458051, NCT04411641) for tolebrutinib in multiple sclerosis show promise in delaying disability progression, especially in non-relapsing SPMS. Though generally well-tolerated, some liver safety concerns led to stricter monitoring and a temporary FDA enrollment hold. The HERCULES trial demonstrates slowed disability progression, with more data expected from the GEMINI and PERSEUS studies in 2025.</li>
                                    <br>
                                    <li><strong>Beijing: </strong>Beijing InnoCare’s Phase 2 trial (NCT04711148) of orelabrutinib for relapsing-remitting MS has shown a strong safety profile, with few adverse effects reported. Interim results indicate the drug significantly reduces brain lesions by up to 92% over 12 weeks, reflecting its potential in slowing disease progression. The BTK inhibitor’s high selectivity and ability to cross the blood-brain barrier contribute to its promising impact on MS-related inflammation.</li>
                                    <br>
                                    <li><strong>Biogen: </strong>The clinical trial NCT05798520, sponsored by Biogen for BIIB091, indicates that the trial is in the recruitment phase, assessing safety and tolerability in relapsing multiple sclerosis patients. The study involves both monotherapy and a combination with diroximel fumarate, with an interim analysis planned after 16 weeks to evaluate early safety data. As this trial progresses, further results on safety and tolerability will be provided.</li>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            
                <!-- Regulatory Milestones -->
                <div class="insight-category">
                    <div class="insight-header safety" onclick="toggleInsight(this)">
                        <div class="header-title">
                            <span class="category-icon">📋</span>
                            Regulatory Milestones
                        </div>
                        <button class="toggle-btn">+</button>
                    </div>
                    <div class="insight-content">
                        <div class="insight-list">
                            <div class="insight-item">
                                <div class="insight-description">
                                <strong> 1.	Tolebrutinib (Sanofi)</strong> 
                                    <br>
                                <li>Received FDA Fast Track Designation</li>
                                    <br>
                                    <li>Phase III trials ongoing as of early 2024</li>
                                    <br>
                                <li>FDA placed partial clinical holds on Phase III trials in 2024 due to liver safety concerns.Hold was partially lifted for some patient populations</li>
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                <strong> 2.	Fenebrutinib (Genentech/Roche)</strong> 
                                    <br>
                                <li>Phase III clinical trials ongoing as of early 2024</li>
                                    <br>
                                <li>FENhance trials investigating its use in RMS and PPMS</li>

                                    
                                </div>
                            </div>
                            <div class="insight-item">
                                <div class="insight-description">
                                <strong> 3.	Orelabrutinib (InnoCare)</strong> 
                                    <br>
                                <li>Received FDA Fast Track Designation for RMS</li>
                                    <br>
                                <li>Phase II trials completed with positive results</li>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    <script>
        function toggleMOA(moa, button) {
            const details = document.getElementById(`${moa}-details`);
            const allButtons = document.querySelectorAll('.moa-button');
            
            // Remove active class from all buttons
            allButtons.forEach(btn => btn.classList.remove('active'));
            
            if (details.style.display === 'none' || !details.style.display) {
                // Hide all MOA details first
                document.querySelectorAll('.moa-details').forEach(detail => {
                    detail.style.display = 'none';
                });
                
                details.style.display = 'block';
                button.classList.add('active');
                initializeCharts(moa);
            } else {
                details.style.display = 'none';
                button.classList.remove('active');
            }
        }

        document.addEventListener('DOMContentLoaded', function() {
            // Drug row click handlers
            document.querySelectorAll('.drug-row').forEach(row => {
                row.addEventListener('click', function(e) {
                    if (e.target.classList.contains('trial-button')) {
                        return; // Don't handle drug row click if trial button was clicked
                    }
                    
                    const drugId = this.getAttribute('data-drug');
                    const insights = document.getElementById(`${drugId}-insights`);
                    
                    // Close all other drug insights
                    // document.querySelectorAll('.drug-insights').forEach(insight => {
                    //     if (insight !== insights) {
                    //         insight.classList.remove('show');
                    //     }
                    // });
                    
                    // Remove active class from all rows
                    document.querySelectorAll('.drug-row').forEach(r => {
                        if (r !== this) {
                            r.classList.remove('active');
                        }
                    });
                    
                    // Toggle current drug insights
                    this.classList.toggle('active');
                    insights.classList.toggle('show');
                    
                    // Close all trial insights when toggling drug insights
                    document.querySelectorAll('.trial-insights').forEach(insight => {
                        insight.classList.remove('show');
                    });
                    document.querySelectorAll('.trial-button').forEach(button => {
                        button.classList.remove('active');
                    });
                });
            });

            // Trial button click handlers
            document.querySelectorAll('.trial-button').forEach(button => {
                button.addEventListener('click', function(e) {
                    e.stopPropagation(); // Prevent drug row click
                    
                    const trialId = this.getAttribute('data-trial');
                    const insights = document.getElementById(`${trialId}-insights`);
                    
                    // Close all other trial insights
                    // document.querySelectorAll('.trial-insights').forEach(insight => {
                    //     if (insight !== insights) {
                    //         insight.classList.remove('show');
                    //     }
                    // });
                    
                    // Remove active class from all trial buttons
                    document.querySelectorAll('.trial-button').forEach(btn => {
                        if (btn !== this) {
                            btn.classList.remove('active');
                        }
                    });
                    
                    // Toggle current trial insights and button state
                    this.classList.toggle('active');
                    insights.classList.toggle('show');
                });
            });
        });


        function initializeCharts(moa) {
            // Phase Distribution Chart
            const phaseCtx = document.getElementById(`${moa}-phase-chart`).getContext('2d');
            new Chart(phaseCtx, {
                type: 'bar',
                data: {
                    labels: ['Phase 1', 'Phase 2', 'Phase 3'],
                    datasets: [{
                        label: 'Number of Trials',
                        data: [0, 4, 6],
                        backgroundColor: '#4299e1'
                    }]
                },
                options: {
                    responsive: true,
                    maintainAspectRatio: false,
                    plugins: {
                        title: {
                            display: true,
                            text: 'Trial Phase Distribution'
                        }
                    }
                }
            });

            // Market Share Chart
            const marketCtx = document.getElementById(`${moa}-market-chart`).getContext('2d');
        new Chart(marketCtx, {
            type: 'pie',
            data: {
                labels: ['Sanofi', 'Novartis', 'Beijing InnoCare Pharma', 'Roche', 'Biogen'],
                datasets: [{
                    data: [30, 20, 10, 30, 10],
                    backgroundColor: ['#4299e1', '#48bb78', '#ed8936', '#9f7aea', '#f56565']
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: false,
                plugins: {
                    title: {
                        display: true,
                        text: 'Market Share Distribution-% (Based on trial count)'
                    },
                    tooltip: {
                        callbacks: {
                            label: function(tooltipItem) {
                                const dataset = tooltipItem.dataset;
                                const total = dataset.data.reduce((acc, value) => acc + value, 0);
                                const currentValue = dataset.data[tooltipItem.dataIndex];
                                const percentage = Math.floor((currentValue / total) * 100);
                                return `${tooltipItem.label}: ${percentage}%`;
                            }
                        }
                    }
                }
            }
        });

        }
        function toggleInsight(header) {
            const content = header.nextElementSibling;
            const toggleBtn = header.querySelector('.toggle-btn');
            const allContents = document.querySelectorAll('.insight-content');
            const allToggleBtns = document.querySelectorAll('.toggle-btn');

            // Toggle current section
            content.classList.toggle('active');
            toggleBtn.textContent = content.classList.contains('active') ? '−' : '+';
        }

    </script>

</body>
</html>
